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With the development of new drugs, there have been many attempts to explore innovative delivery
routes. Targeted delivery systems are a desired solution designed to overcome the deficiency of routine
methods. To transform this idea into reality, a wide range of nanoparticles has been proposed and
studied. These nanoparticles should interact well with biological environments and pass through cell
membranes to deliver therapeutic molecules. One of the pioneer classes of carbon-based nanoparticles
for targeted delivery is the fullerenes. Fullerenes have a unique structure and possess suitable properties
for interaction with the cellular environment. This short review concentrates on newly developed
fullerene derivatives and their potential as advanced delivery systems for pharmaceutical applications.Introduction
Routine methods for drug administration involve pulmonary,
transdermal, transmucosal, ocular and other delivery systems
among which injection and oral delivery are the most popular
[1]. In these methods, one of the main problems is the poor
pharmacokinetics and untargeted delivery of the drugs; therefore,
in some applications such as chemotherapy there are increasing
side-effects from the drug and the effectiveness of therapy could
decrease. Beside the delivery of drugs, in some diseases there is also
a need to deliver biological substances such as DNA and various
small molecules through the cell membrane. In fact, the delivery
of such substances to the nucleus and other organelles can engen-
der new challenges owing to the specific barriers and features
present in the cell.
To overcome these challenges, research in nanotechnology has
offered a range of solutions to enhance the drug delivery effective-
ness [2]. For instance, the pioneer nanoparticle: fullerene, with a
specific geometry, size and surface characteristics, possesses a
uniquely spherical structure with a strong apolar character [3].Corresponding author: Mozafari, M. (mozafari.masoud@gmail.com)
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serving as a reservoir and even crossing cell membranes [4].
Structural features and activities
Fullerenes, also referred to as Buckminsterfullerenes or Buckyballs,
are one of the allotropes of the carbon family of nanomaterials [5].
Fullerenes exhibit a structure consisting of sp2 carbons that present
unique chemical and physical properties and a highly symmetrical
cage with different sizes (C60, C76, etc.) [6,7]. The most abundant
fullerene in the synthesized composition is C60 [4]. It consists of
60 carbon atoms with C5–C5 single bonds (12 pentagons), and
C5 = C6 double bonds (20 hexagons). Indeed, each fullerene with
2n + 20 carbon atoms contains ‘n’ hexagons. C60 and C70 are
produced at 1000 C and the concentration increases as pulse
duration increases [8]. Among different characteristics of this
molecule, the dual behavior of C60 among reactive oxygen species
(ROS) gave this nanoparticle the ability to act in different ways in
specific situations. In some cases, C60 has the ability to produce
oxygen species upon exposure to visible light, making it a suitable
candidate for photodynamic therapy (PDT). In some other cases, it
downregulates ROS, which can be used as a neuroprotective agent1359-6446/ã 2019 Elsevier Ltd. All rights reserved.
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[9]. The mechanism of this action is still unknown and requires
further investigation. An obstacle in exploiting this molecule in
biological applications is its insolubility in water and low solubility
in many organic solvents. Accordingly, in biological systems, the
hydrophilicity of materials has greater importance in comparison
with hydrophobicity and many methods have been used to in-
crease its hydrophilicity and water solubility [4]. These include the
preparation of two-phase colloidal solutions, synthesizing fuller-
ene derivatives, fullerene polymers, encapsulation in special car-
riers (cyclodextrins, calixarenes, polyvinylpyrrolidone, micelles,
liposomes, etc.), chemical modification [by adding hydrophilic
substances such as amino acids, carboxylic acids, polyhydroxyl
groups (fullerenols) and amphiphilic polymers], among others.
Applications in pharmaceutics
Nucleic acid delivery
Owing to their specific abilities, there have been several attempts
to use fullerene and its functionalized derivatives for pharmaceu-
tical applications (Fig. 1). Materials from this class can potentially
act as targeted and controlled drug delivery systems. Nucleic acid









Fullerene-based delivery systems. Nucleic acid delivery: penetration through cell m
delivery to cancer cells andactivationof ROS systemowingto theactivation of photos
agents anddecreasingsideeffectsand increasingefficacy; heartdelivery: targeteddel
increasing efficacy; brain delivery: unique nanostructure and appropriate interaction
uniqueandflexiblestructureand good interactionwithkeratinocytes;anti-HIV-1activ
anti-oxidant activity: downregulating the ROS system and inactivating the oxygen its functionalized derivatives. The process is about targeted deliv-
ery in cells with nucleic acid deficiency. Most approaches use viral
delivery for the transfer of DNA, RNA, siRNA, LNA and plasmid
DNA to specific cellular locations [10]. In some studies, nanopar-
ticles, such as fullerenes especially cationic ones, were used to
deliver small molecules owing to their nonimmunological reac-
tions, low cost and high efficacy [11]. A water-soluble cationic
tetra-amino fullerene and siRNA form submicrometer complexes
in a buffered solution [12]. It can be said that these complexes
agglutinate further with plasma proteins in the bloodstream to
form micrometer particles. The agglutinate rapidly clogs the lung
capillaries, releases the siRNA into lung cells to silence the expres-
sion of targeted cancer genes and is then cleared rapidly from the
lung after siRNA delivery [12]. In other research, C60-Dex-NH2
with a specific amphiphilic skeleton formed micelle-like aggregate
structures in water, which could prevent siRNA from being
destroyed by ROS. As it was exposed to visible light, C60-Dex-
NH2 triggered controllable ROS generation causing lysosome
membrane destruction, promoted lysosomal escape and enhanced
gene silencing efficiency of siRNA in vitro and in vivo. The gene
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embrane and non-immunological reaction; photosensitizer delivery: targeted
ensitizer by UV light; cancer celldelivery: targeted delivery ofchemotherapeutic
ivery ofhighlypotentcardiovascularmedicines anddecreasingside-effectsand
 with tight assembled cellular structure of blood–brain barrier; topical delivery:
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species as neuroprotective and antiaging agents.
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EENMDA-MB-231-EGFP cells and 69% in the 4T1-GFP-Luc2 tumor-
bearing mice [11]. The reported data in the literature support the
use of conjugated nucleic acids with fullerene-based delivery
systems to significantly enhance the efficacy in a target-specific
manner. There is growing interest toward this strategy because the
healthy cells are somewhat less vulnerable to adverse reactions.
Topical drug delivery
Antioxidant activity of fullerenes and interactions with epidermal
keratinocytes enabled this spectacular nanomaterial to have enor-
mous abilities to be used in transdermal delivery and cosmetic
applications [13]. Owing to their antioxidant activity and the ease
of topical delivery, this class of materials has been frequently used
in different forms, such as moisturizers, anti-inflammatory sub-
stances, cytoprotective, UVB inhibitory and barrier-repair agents,
hair growth stimulators and antimelanogenesis agents [14,15].
In the area of drug delivery, fullerene-based peptides were
examined and the results demonstrated adequate penetration,
as related to mechanical flexion [16]. Basic cosmetic formulations
with transcutol/isopropyl myristate without harsh organic sol-
vents showed a high potential for applications in biopharmaceu-
ticals and cosmetics [17]. Furthermore, there are a few reports on
the use of noncovalently adsorbed drugs and fullerenes (showing
reasonable stability at room temperature); therefore, at an opti-
mum concentration they could present acceptable and efficient
transdermal drug delivery [18,19].
Cancer therapy
Cancer is the uncontrolled growth of abnormal cells in the body
and is caused by many factors such as chemical or toxic com-
pounds, ionizing radiation, pathogens and human genetics [20].
Many drugs with different effects have been used to treat cancer.
The main problem in cancer therapy is the significant side-effects
of the drugs, and they require targeted delivery [21]. Another
drawback in cancer treatment is drug resistance; therefore, there
is a need for the use of multiple drugs, which further increases their
negative side-effects.
One promised nanoparticle in drug delivery is fullerene with its
strong structural features. Fullerene, with the ability of carrying a
multiple drug payload and with targeted drug delivery, could solve
many of the side-effects of chemotherapy [22,23]. For instance, the
cardiomyopathy-related side-effects of doxorubicin made this
compound a candidate for conjugation with fullerene [24]. This
conjugation was examined at different pH values and the results
demonstrated 100% drug release at pH 5.25. The results enable us
to use this conjugation for targeted drug delivery and to decrease
side effects. The challenge in this approach was that doxorubicin
was water-soluble whereas fullerene was hydrophobic, so ethylene
glycol spacers were used for conjugating methano-C60 with doxo-
rubicin, improving the water solubility of this conjugation [4]. In
another study, Buckysomes, spherical nanostructures that are
made of amphiphilic fullerenes with hydrophobic regions, were
used to mask the hydrophilic surface of paclitaxel. This study
indicated that the proposed complex could effectively enhance
drug absorption [25].
A new, novel drug delivery system was based on an ‘on–off’ drug
delivery strategy developed by the conjugation of doxorubicin and
fullerene after attachment of a hydrophilic shell to the outer surface900 www.drugdiscoverytoday.comof the conjugation. This drug delivery system is very stable in
physiological solutions even with a pH 5.5 in the ‘off’ state; by
contrast, inthe ‘on’statethe generation ofROSbyfullereneresults in
two treatment types. First, generation of oxygen species and causing
cell death (PDT) and, second, the breaking of the ROS-sensitive
linkers, enabling the exploding release of doxorubicin (chemother-
apy) [26]. It should be mentioned that, in the development of
innovative strategies for cancer treatment, especially in chemother-
apy and PDT, many nanomaterials have been tested so far but
fullereneand fullerene-based systemsareamongthemostpromising
candidates owing to their unique structures and properties.
Photodynamic therapy
Over the past decades, PDT has proved its potential in the treat-
ment of a series of diseases ranging from bacterial infection to
cancer [27]. This method is based on the absorption of photo-
sensitizers in targeted tissue, activation by a specific wavelength,
activation of the ROS system and oxygen species and, finally,
subsequent cell death [28]. A key limitation in PDT is the poor
water solubility of many photosensitizers [29,30]. Some of the
great advantages of fullerenes include their potential in PDT – the
absorption of visible light combined with an efficient intersystem
crossing to a long-lived triplet state that makes fullerenes generate
ROS upon illumination and allows fullerenes to act as photosen-
sitizers [4]. Many substances conjugated with fullerenes have been
synthesized in past years. In innovative research, iron oxide nano-
particles (IONPs) were first decorated on the surface of fullerenes
and then PEGylated. C60-IONP-PEG nanocomposite demonstrat-
ed a strong superparamagnetism and powerful PDT capacity [31].
In another study, C60-lysozyme showed effective endogenous ROS
activity after exogenous H2O2 generation owing to its photody-
namic activity in HeLa cells [32].
With the aim of developing smart photosensitizers with tumor-
microenvironment-activatable fluorescence turn-on and singlet
oxygen generation for tumor bioimaging and PDT, Tang et al.
[33] proposed that a pH-sensitive photosensitizer, C60-rhodamine
B, having a spirolactam structure, was activated in acidic pH by its
ring-opening structure. In this system, enhancement of visible
light absorption and singlet oxygen generation occurred.
Advances in this field suggest that PDT can be considered as a
strong treatment method owing to the massive terminating effect
on cells such as cancer cells. But the main problem was that the
effect on healthy cells was equal to cancer cells. Fullerene-based
delivery systems could begin to solve this problem. This class of
materials, with the ability of targeted delivery, decreased the
absorption in healthy cells and increased it in cancer cells. This
supreme ability of fullerene-based delivery systems should be
noted and more experiments should be conducted to be used in
clinical applications.
Crossing the blood–brain barrier
The blood–brain barrier is a physical barrier composed of endo-
thelial tight junctions that inhibit the paracellular permeability
and therefore create a major challenge for delivering drugs to the
central nervous system (CNS) [34]. Fullerene and its water-soluble
derivatives are among the nanomaterials with a high potential for
delivering drugs into the CNS. In a study, a complex of fullerene
and hexamethonium was developed and compared with the












hexamethonium delivery system alone. The research demonstrat-
ed a 40-times boosted potency in the complex drug delivery
system [35]. In another study, water-soluble C60 fullerene deriva-
tives with four types of linkages between the fullerene cage and the
solubilizing added atoms were synthesized [36]. Fullerene deriva-
tives 1–6 (compounds 1–3: C–C bonds; compounds 4–5: C–S
bonds; compound 6: C–P bonds) were observed to induce neural
stem cell (NSC) proliferation in vitro and rescued the function of
the injured CNS in zebrafish. Surprisingly, compound 3 bearing
residues of phenylbutyric acid significantly promoted NSC prolif-
eration and neural repair with a change in the metabolism of cells
by reducing ROS activity and Inducing ATP activity. Fullerene
derivatives 7–9 (compounds 7–9: C–N bonds) were found to act as
glioblastoma cell proliferation inhibitors in zebrafish. Compound
7 with phenylalanine appendages significantly inhibited glioblas-
toma growth; therefore, acting as an antitumor agent. This effect
was also correlated to the cell metabolic changes in the tail of the
induced ROS activity and reduced ATP activity [36]. In addition,
carboxyfullerenes have been exploited in the treatment of neuro-
degeneration caused by amyotrophic lateral sclerosis (ALS) [37].
The tight complex structure of the brain does not naturally let any
chemical pass the barrier. As stated, fullerene-based delivery sys-
tems do not usually obey this rule, being able to deliver therapeu-
tics through their twisted structures.
Antioxidant activity and radical scavenging
Balanced oxidation and antioxidant activity of the body is indeed
an important function for the safety of our biological system. With
our incomplete endogenous antioxidant defense system and mas-
sive free-radical production by our normal cellular metabolism as
well as abnormal reactions, there is always a need for exogenous
antioxidants to prevent toxicities and diseases caused by excess
free radicals such as cancer and atherosclerosis [38]. The presence
of several double bonds in the fullerene cage makes this class of
nanoparticles capable of reacting with free radicals such as super-
oxide, hydroxyl radicals and hydrogen peroxide [4]. In a recent
study, two different fullerenes, C60 and C82, conjugated with
three transition metals (i.e., copper, silver and gold) were used as
an antioxidant. The results demonstrated that the antiradical
capacity of fullerenes was boosted as a result of the presence of
the metals [39]. In other research, the antioxidant ability of
fullerene was used in cosmetics and skincare products as an anti-
ageing agent [40]. With the ability of crossing the blood–brain
barrier, a suspension of fullerene with a maximum size of 450 nm
was prepared and injected into the hippocampi of Wistar rats.
Although the results demonstrated impaired spatial memory with
a significant decrease in brain-derived neurotrophic factor (BDNF)
protein levels, a decrease in ROS was also observed [41]. Antioxi-
dant activity of fullerenols in oxidizer solutions with luminous
bacteria and their enzymes was tested. The results demonstrated
that the effect on bacterial cells was attributed to the hormesis
phenomenon, whereas the intensification of biochemical reac-
tions was related to its catalytic activity [42]. One of the most
important problems for citizens today is related to oxidative stress.
It is expected that fullerene-based systems could balance the
oxidative stress system. Many investigations should be conducted
to fully understand the vital role of fullerene-based delivery sys-
tems in controlling oxidative stress.Anti-HIV activity of fullerenes
HIV is a lentivirus (a retrovirus subgroup) that ultimately causes
AIDS [43]. With the lack of immune activity, the patient dies either
by cancer or opportunistic infections [44]. In acknowledging the
mechanism-of-action of HIV, many drugs such as nucleic and non-
nucleic reverse transcriptase inhibitors, protease inhibitors, and so
on, have been synthesized [45]. There are several reports on
fullerene and its ability to inhibit HIV-1 protease activity. The
active site is a semi-open hydrophobic ellipsoid, with Asp-25 and
Asp-125 standing out on the surface of the cavity and catalyzing
the protease function. So the antiviral activity was caused by the
entrance of fullerene into the pocket, attaching to the active site
via van der Waals interactions [46]. Some derivative fullerenes
inhibit HIV-1 viruses that are multidrug-resistant [47]. The mech-
anism-of-action was suggested to be via a strong interaction with
the immature capsid in pull-down experiments. No toxicity oc-
curred during the treatment with these compounds; therefore,
they could be among the next-generation candidates for HIV
treatment [47]. Furthermore, HIV-1 reverse transcriptase inhibito-
ry activities of cationic, anionic and zwitterion fullerene deriva-
tives were tested, in which cationic derivatives showed lower
activity [47]. Pyridine/pyridinium-type fullerene derivatives with-
out any carboxylic acid inhibit the HIV-1 reverse transcriptase in a
cell-free environment. The results showed the important role of
the fullerene cage without any sign of cytotoxicity [48]. Many
approaches for HIV treatment consist of vaccines and/or drugs, in
which vaccines are of great interest. HIV is a special virus with an
amazing lifecycle that has a supreme defense against drugs. Ful-
lerene-based delivery systems could be the answer to control this
virus and its lifecycle, but we shall see what this system can do
through further investigation.
Antibacterial activity of fullerenes
Along with many antibacterial agents such as beta lactams, several
functionalized fullerene derivatives showed acceptable inhibitory
effects on bacteria. Carboxyfullerene antibacterial activity was ex-
amined against Streptococcus pyogenes infection. In vitro experiments
showed that this derivative could suppress growth of S. pyogenes and
its administration could protect 33% of mice from death [4]. Fur-
thermore, this compound exhibited more activity against Gram-
positive bacteria than Gram-negative bacteria (almost none).
The biological responses against alkaline-synthesized fullerenol
were examined on Pseudomonas aeruginosa and Staphylococcus au-
reus. The results demonstrated that toxicity thresholds for com-
mercially prepared fullerenol were lower for all species, which was
attributed to the presence of impurities. A mechanistic analysis of
membrane damage on bacteria by laboratory-prepared fullerenol
indicated necrotic and apoptotic responses with and without
photoactivation [49].
It has been frequently reported that fullerenes could directly
interact with biomolecules, such as aromatic mutagens or anti-
cancer drugs. In a recent study, aqueous solutions containing C60
and an aromatic mutagen called ICR-191 were prepared and
further evaluated against Salmonella typhimurium. The results dem-
onstrated a massive affinity to the bacterial cell wall that altered
cellular morphology [50].
C60/C3N4and C70/C3N4hybridssynthesizedbya hydrothermal
method exhibited stronger bacterial inactivation than C3N4 againstwww.drugdiscoverytoday.com 901








EENEscherichia coli O157:H7. The enhancement of photocatalytic activi-
ty of composites could be attributed to the effective transfer of the
photoinduced electrons under visible light irradiation [51]. Bacteria
are the most familiar microorganisms and many types of them are
completely understood. The main problem is the development of
their mechanisms and increasing antibiotic resistance. It is expected
that proposing innovative delivery systems could provide us with
alternative solutionsforbacterial resistance tocontrol and terminate
bacteria in a different mechanism to that of antibiotics.
Fullerenes as neuroprotective agents
Excess production of oxygen species and hyperactivation of N-
methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) and glu-
tamic receptors can lead to neurodegenerative diseases such as
Alzheimer’s and Parkinson’s [52]. Radical scavenging ability, ROS
activation and ability to interact with peptides were the main
reasons for the usage of fullerene derivatives in neurodegenerative
diseases [4]. Their ability to interact with peptides was also used to
prevent formation and progression of Alzheimer’s disease. In a
study, the effect of hydrophobic fullerene C60 on the oligomeric
structures of the hydrophilic GNNQQNY peptide, the key amy-
loid-forming fragment of yeast prion protein Sup35, was tested
[53]. The results demonstrated that fullerenes completely prevent
fibril-like bilayer b-sheets, formed by GNNQQNY peptides, and
also blocked the inter-peptide interactions that are crucial for
oligomerization and b-sheet formation [53]. In some innovative
research, UCNP@C60–pep under near-infrared light produced ROS
species, in which the oxygen species hindered A-beta and mitigat-
ed attendant cytotoxicity [9]. Fullerene and fullerenols have
shown spectacular antioxidant activity. Their abilities to reduce
apoptosis in cortical neurons and to block glutamic acid receptors
have been reported [54]. Hexa(sulfobutyl) fullerenes and trimesic
acid (TMA) fullerenes also demonstrated their ability to trap free
radicals and play an efficient part in the treatment of neurodegen-
erative diseases [55,56]. Based upon various studies, water-soluble
derivatives, such as fullerenols and malonic acid fullerenes, can
react with hydroxyl and superoxide free-radicals and reduce neu-
ronal degeneration related to ROS [57]. Neurodegenerative dis-
eases are developing rapidly, reducing quality-of-life whether
physical or social. This could be related to life expectancy increas-
ing and systemic deficiency occurring in the body over time. With
the use of fullerene-based delivery systems we can overcome,
control or prevent this major problem.
From basic findings toward clinical applications
One of the most important approval tests in drug manufacturing
processes after evaluation in animal models is promising clinical
trials. Owing to their superior advantages over conventional de-
livery systems, there have been several attempts to take advantage
of nanocarriers for the delivery of drugs. For the case of fullerene-
based delivery systems, despite the incredible abilities mentioned
in the previous sections, no clinical trials have been announced yet
[58]. One of the most important obstacles restricting this approach
from human usage is the inherent toxicity of fullerene nanoma-
terials [58]. Nowadays, a series of tests conducted by several
independent teams, such as C60 nanoaggregates prepared with
tetrahydrofuran (THF), confirmed the safety of pure C60 in various
experimental models in the laboratory [59]. Although there have902 www.drugdiscoverytoday.combeen some scattered reports in the literature, there is still a long
way to go before we fully understand the actual performance and
function of this class of nanomaterials. Several successful preclini-
cal trials have been conducted in different animal models, indi-
cating that there is a need for clinical evaluation.
In recent innovative research, hydroxylated fullerenes have
been used to investigate the analgesic effect in clinically relevant
lumbar radiculopathy [60]. Remarkably, single and local use was
sufficient to decrease ipsilateral paw pain sensation in mice up to 2
weeks post-surgery. Furthermore, micro-CT data suggested that
hydroxylated fullerenes potentially promoted disc height recovery
following injury-induced disc herniation. To understand the
mechanism of these effects, an in vitro study on mouse dorsal root
ganglia (DRG) culture demonstrated that fullerol attenuated tu-
mor necrosis factor (TNF)-a-elicited expression of transient recep-
tor potential cation channel subfamily V (TRPV)-1 and
neuropeptide release (substance P and calcitonin gene-related
peptide). This action was mentioned to be through protein kinase
B (AKT) and extracellular protein regulated kinase (ERK) pathways.
Furthermore, Alcian blue and picrosirius red staining also sug-
gested that fullerol promoted regeneration of extracellular matrix
proteins visualized by the presence of abundant, newly formed
collagen and proteoglycan in herniated discs (Fig. 2).
In other research, a lethal pulmonary disease called pulmonary
fibrosis was tested via inhalation of gadofullerenol (GF-OH) and
fullerenol nanoparticles [61]. The results demonstrated that gado-
fullerenols and fullerenols substantially decreased the collagen
deposition induced by acute lung injury. The mechanism-of-ac-
tion was observed to be via antioxidant and anti-inflammatory
functions for the modulation of ROS-mediated inflammation and
indirectly modulating transforming growth factor (TGF)-b1 ex-
pression (Fig. 3). Furthermore, gadofullerenol exhibited a higher
performance than fullerenol owing to the larger quantity of the
residual conjugated double bonds.
In a study by Chen et al. [62], carboxyfullerenes were used in rat
models in acute hepatic injury caused by severe hemorrhagic shock.
In hemorrhagic shock there is a great deal of activity of the ROS
system, which could further lead to oxidative stress, inflammation
and subsequent tissue injury. The results demonstrated a decrease in
alanine aminotransferase (ALT) activity, methemoglobin content,
malondialdehyde content and myeloperoxidase activity. Carboxy-
fullerenes also decreased levels of TNF-a and interleukin (IL)-6 with
anincreaseinsuperoxidedismutase activityintheliver. It seems that
these protective effects are related to the inhibition of the nuclear
factor (NF)-kB pathway via reducing phosphorylation of the NF-kB
p65 subunit in the liver.
It is worth mentioning that all of the stated preclinical trials
could have some similarities to the mechanism in humans but the
main obstacle is that the human body is a special case and
sometimes acts differently from data collected in animal tests.
Despite many criticisms, the use of fullerenes for delivery purposes
remains a very attractive concept and should be contemplated
very carefully. Addressing this, this article offers another proof-of-
concept toward better understanding the essential factors govern-
ing different aspects of fullerene delivery systems. Although some
researchers have previously confirmed preclinical success, recent
debates failed to comprehensively discuss and acknowledge the
effectiveness of fullerene delivery systems in the clinic.
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FIGURE 2
Hydroxylated fullerene to treat lumbar radiculopathy. (a) Schematic hypothesis of therapeutic mechanism of fullerol in lumbar radiculopathy secondary to disc
herniation. (Upper row) in vitro mechanism via antagonizing TNF-a-induced neuroinflammation and alternation in nociceptive factors, ion channel, intracellular
[Ca2+] and signaling pathways in DRG. (Lower row) in vivo regenerative effect in clinical model of lumbar radiculopathy secondary to disc herniation. (b) Micro-CT
image of mouse spine 2 weeks after surgery indicated restored disc height via fullerol restoring effect. (c) The injury + fullerol group showed an increase in the
ratio of L4–5:L5–6 PDH. (d) Alcian blue/picrosirius red staining models demonstrating ongoing regenerative process of injured IVD post-fullerol treatment. After
2 weeks post-surgery, compared with intact disc (top row), injury + saline (middle row) discs demonstrated classical manifestations of disc degeneration such as
ruptured lamina, enlarged and proliferated chondrocytes. The fullerol-treated group (bottom row) demonstrated much better purple staining in the inner and












The state-of-the-art and future perspectives
With the growing interest in the use of fullerene-based delivery
systems, many innovative systems are being proposed. Although
there are many promising examples, there is still room for more-
advanced systems against challenging diseases. In the first case
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FIGURE 3
Inhalable gadofullerenol/[70] fullerenol for pulmonary fibrosis therapy.
Inhalants containing gadofullerenol and fullerenol nanoparticles with
excellent free-radical scavenging ability were used as an essential therapy for
pulmonary fibrosis. Both of them effectively attenuated bleomycin (BLM)-
induced acute lung injury. The mechanism-of-action was due to
improvement of collagen accumulation and reduction in oxidative stress
damage. These events are related to direct ROS modulating ability and
indirect inducing TGF-b1 expression accomplished by gadofullerenol and
fullerenol. Furthermore, gadofullerenols displayed better antioxidant activity
owing to the larger quantity of the residual conjugated double bonds.
Reproduced, with permission, from Ref. [61].particles designed for targeted delivery, porphyrin adducts of
cyclohexyl-fullerene were prepared for the delivery of Mg2+ to
the myocardium [63]. In a single injection, release of Mg2+ due to
the acidic metabolic shift by nanoparticles was used to stimulate
ATP overproduction in oxygen-depleted cells and, therefore, 80%
of the tissue that was suffering from hypoxia was recovered after
24 h. The positive changes in heart cell energy metabolism could
assist in the treatment and prevention of local myocardial hypoxic
disorders and protect heart muscles in different hypoxia-caused
clinical situations.
Fullerenes also have been used in delivery of highly bioactive
molecules like warfarin – a coumarin anticoagulant drug [64]. This
drug has shown a very low therapeutic index and therefore is
indeed a candidate for drug delivery in order to adjust its dosage.
Conjugation of warfarin to fullerene can alter its biological profile
and prevent variation of its concentration in the blood. Further-
more, this conjugate modulates warfarin dosage and makes this
drug controllable. This is an important concept that should be
further developed.
Erythropoietin (EPO), a hormone mainly produced by the kid-
neys, which increases red blood cell production, can also be linked
to fullerenes and can be used in diseases such as bone marrow
suppression [65]. Upon i.v. injection of EPO, its biological activity
is reduced abruptly. To overcome this problem, nanoparticles of
EPO were synthesized for effective administration of EPO. For
instance, EPO was absorbed on porous materials containing ful-
lerene and its bioavailability studied via pharmacokinetics and the
results demonstrated three-times higher bioavailability than intra-
peritoneal administration.www.drugdiscoverytoday.com 903








EENAmong the mentioned conjugated nanoparticles, some poly-
conjugated fullerenes were used to treat cancer. Conjugation of
malonodiserinolamide plus fluorophore and fullerene exhibited
promising outcomes in in vivo liver cancer therapy and breast
adenocarcinoma in murine cells [66]. In other research, conjugat-
ed PEI-C60-folic-acid-(via an amide linker)-docetaxel exhibited
reasonable cell membrane permeation, increasing the apoptosis
and decreasing the possible side-effects of the docetaxel. Further-
more, conjugation of hyaluronic acid with transferrin showed
high efficacy in PDT [67].904 www.drugdiscoverytoday.comConcluding remarks
In this concise review, many fullerene derivatives have been
mentioned and their uses in different pharmaceutical applications
have been discussed. With the specific structure and methods used
to increase water solubility, there is no doubt that fullerene-based
delivery systems offer many opportunities in disease treatment.
For this to be realized, more in vivo tests should be conducted
before clinical examinations. Systemic pharmacokinetics, toxico-
logical studies, therapeutic index and side-effects must be under-
stood. With the significant input that will be gained from in vivo
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